Michael C. Milone, MD, PhD

Frazee CS, Chen S, Berry CT, Lee CS, Banciella RA, Ngo L, Shon D, Herman PJ, Fischman JS, Leff CL, Chen A, Kuo Y, Shestov AA, Kelly AR, Valentic B, Milone MC, O'Connor RS, Ellebrecht CT. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains , Nat Immunol: 2026

Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A., Shestov, A., Xu, H. N., Carturan, A., Zhou, C., Amses, K. R., Afriat, A., Litichevskiy, L., Lin, J., Dubowitz, E., Tangal, N., Zhang, J., McSween, A., Tan, M., Stella, F., Lee, A., Nason, S., Hua, X., Schneider, M., Sleeman, M., Zhang, Y., Gabrielli, G., Yang, Z., Pajarillo, R., Patel, R., Ghilardi, G., Patel, V., Joshi, A., Jiang, S., Jiang, Y., Porazzi, P., Tchou, J. C., Keith, B., Li, M., Chong, E., Schuster, S. J., Milone, M., Rabinowitz, J., O'Connor, R. S., Thaiss, C. A., Levy, M., Ruella, M. β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer , Cell: 2026

Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, Chen L, Wilkins K, Baker DJ, Rommel PC, Jarocha D, Gohil M, Zhang Q, Milone MC, Fraietta JA, Davis M, Young RM, June CH. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells , Proc Natl Acad Sci U S A, 122: 2025,e2427216122

Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis , Cancer Chemother Pharmacol, 95: 2025,32

Zhang, Qian, Wu, Yihao, Yang, Jingyi, Zhou, Kevin, Anand Manoharan, Eric Nigel Ebenezer, Wentz, Tyra, Su, Leon, Yu, Alvin, Wang, Hong-Yi, Bruhn, Laurakay, Steinfeld, Israel, Gonzalez, Nicolas, Song, Edward Z., Zhang, Yunlin, Hresko, Morgan E., Ryan, Daniel E., Engel, Nils W., Nunez-Cruz, Selene, June, Carl H., Garcia, K. Christopher, Milone, Michael C. Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor , Blood Immunology & Cellular Therapy, 1(3): 2025

Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., Weber, E., Napier, E., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Milone, M. C., O'Connor, R., Schuster, S. J., Ruella, M. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines , Blood Adv, 8(3): 2024,653-666

Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies , Cell Rep Med, 4: 2023,101336

Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, Greene MI. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer , Biochem Biophys Res Commun, 680: 2023,51-60

Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells , Nat Biotechnol, 41(9): 2023,1229-1238

Glisovic-Aplenc, T., Diorio, C., Chukinas, J. A., Veliz, K., Shestova, O., Shen, F., Nunez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., June, C. H., Teachey, D. T., Tasian, S. K., Aplenc, R., Gill, S. CD38 as a pan-hematologic target for chimeric antigen receptor T cells , Blood Adv, 7(16): 2023,4418-4430